BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pegozafermin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pegozafermin\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07835243-1159@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20270302
DTEND;VALUE=DATE:20270303
SUMMARY:Pegozafermin: Phase 1 readout est. (NCT07835243)
DESCRIPTION:Pegozafermin\, phase 1.\nStudy: A Study to Assess the Effect of
  Subcutaneous Injection Site on the Pharmacokinetics of Pegozafermin in He
 althy Participants\nEstimated primary completion: 2 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pegozafermin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07835243
URL:https://assetmemo.bio/drug/pegozafermin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06419374-1159@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pegozafermin: Phase 3 readout est. (NCT06419374)
DESCRIPTION:Pegozafermin\, phase 3\, MASH / NASH.\nStudy: A Study to Evalua
 te the Efficacy and Safety of Pegozafermin in Participants With Compensate
 d Cirrhosis Due to MASH\nEstimated primary completion: 30 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pegozafermin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06419374
URL:https://assetmemo.bio/drug/pegozafermin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06318169-1159@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Pegozafermin: Phase 3 readout est. (NCT06318169)
DESCRIPTION:Pegozafermin\, phase 3\, MASH / NASH.\nStudy: A Study Evaluatin
 g the Efficacy and Safety of Pegozafermin in Participants With MASH and Fi
 brosis (ENLIGHTEN-Fibrosis)\nEstimated primary completion: February 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pegozafermin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06318169
URL:https://assetmemo.bio/drug/pegozafermin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
